This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2019 May 1;5(5):605-606.

doi: 10.1001/jamaoncol.2018.7229.

HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer

Giacomo Bregni¹, Stefania Sciallero¹, Alberto Sobrero¹

Affiliations

PMID: 30869746
DOI: 10.1001/jamaoncol.2018.7229

HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer

Giacomo Bregni et al. JAMA Oncol. 2019.

. 2019 May 1;5(5):605-606.

doi: 10.1001/jamaoncol.2018.7229.

Authors

Giacomo Bregni¹, Stefania Sciallero¹, Alberto Sobrero¹

Affiliation

¹ Ospedale Policlinico San Martino IRCCS, Genoa, Italy.

PMID: 30869746
DOI: 10.1001/jamaoncol.2018.7229

No abstract available

PubMed Disclaimer

Similar articles

Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
Wang G, He Y, Sun Y, Wang W, Qian X, Yu X, Pan Y. Wang G, et al. Clin Transl Oncol. 2020 Jun;22(6):813-822. doi: 10.1007/s12094-019-02213-9. Epub 2019 Oct 5. Clin Transl Oncol. 2020. PMID: 31587152 Review.
Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer.
Zhang R, Su C, Jia Y, Xing M, Jin S, Zong H. Zhang R, et al. Biomed Pharmacother. 2024 Oct;179:117363. doi: 10.1016/j.biopha.2024.117363. Epub 2024 Sep 4. Biomed Pharmacother. 2024. PMID: 39236476 Review.
Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D, He AR, Hwang J, Deeken J, Pishvaian M, Hartley ML, Marshall JL. Subramaniam D, et al. Curr Cancer Drug Targets. 2015;14(9):775-93. doi: 10.2174/1568009614666141111104643. Curr Cancer Drug Targets. 2015. PMID: 25435079 Review.
Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Berezowska S, Diermeier-Daucher S, Brockhoff G, Busch R, Duyster J, Grosu AL, Schlegel J. Berezowska S, et al. Int J Mol Med. 2010 Nov;26(5):713-21. doi: 10.3892/ijmm_00000518. Int J Mol Med. 2010. PMID: 20878094
Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.
Fakih MG. Fakih MG. Oncologist. 2018 Apr;23(4):474-477. doi: 10.1634/theoncologist.2017-0436. Epub 2018 Jan 12. Oncologist. 2018. PMID: 29330210 Free PMC article.

See all similar articles

Cited by

HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer.
Nakamura Y, Sawada K, Fujii S, Yoshino T. Nakamura Y, et al. ESMO Open. 2019 Jul 8;4(3):e000530. doi: 10.1136/esmoopen-2019-000530. eCollection 2019. ESMO Open. 2019. PMID: 31354963 Free PMC article. No abstract available.
Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer.
Xu X, Liu M, Peng K, Yu Y, Liu T. Xu X, et al. Clin Transl Oncol. 2023 Mar;25(3):776-785. doi: 10.1007/s12094-022-02986-6. Epub 2023 Jan 7. Clin Transl Oncol. 2023. PMID: 36609651 Free PMC article.
Towards the era of precision medicine in metastatic colorectal cancer.
Napolitano S, Troiani T, Martinelli E, Ciardiello F. Napolitano S, et al. ESMO Open. 2020 Mar;5(2):e000685. doi: 10.1136/esmoopen-2020-000685. ESMO Open. 2020. PMID: 32220949 Free PMC article. No abstract available.
Emerging actionable targets to treat therapy-resistant colorectal cancers.
Grassilli E, Cerrito MG. Grassilli E, et al. Cancer Drug Resist. 2022 Jan 4;5(1):36-63. doi: 10.20517/cdr.2021.96. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35582524 Free PMC article. Review.
The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
Ros J, Baraibar I, Martini G, Salvà F, Saoudi N, Cuadra-Urteaga JL, Dienstmann R, Tabernero J, Élez E. Ros J, et al. Curr Treat Options Oncol. 2021 Nov 6;22(12):113. doi: 10.1007/s11864-021-00913-5. Curr Treat Options Oncol. 2021. PMID: 34741675 Review.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal